Nordion to host European-based educational and scientific meetings for liver cancer specialists

288

Nordion is to host two upcoming educational and scientific meetings to support the growth and expansion of TheraSphere treatment in Europe. On 11–12 April, Nordion will host its 3rd European TheraSphere User Group Meeting in Vienna, Austria, and on 18 April, Nordion will offer a Satellite Symposium at the 3rd Interdisciplinary Treatment of Liver Tumors (ITLT) Meeting in Essen, Germany, according to a company release.

“These meetings provide physicians with an opportunity for interactive, real-time discussions on industry best practices and trends in radioembolization and liver cancer therapy,” said Steve West, Nordion CEO and chief operating officer, Targeted Therapies. “With the objective of expanding the adoption of TheraSphere in Europe and further developing our clinical program, these events help us share the latest developments in radioembolization to a broad physician base from various liver cancer disciplines.”

The 3rd European TheraSphere User Group Meeting will cover a variety of topics over two days with a focus on current and future trends in radioembolization presented by speakers from Italy, Germany, France and the USA.

According to the release, the ITLT Satellite Symposium titled “Clearly targeted! Looking beyond systemic therapies for the treatment of liver cancer” is intended to provide attendees with the latest data on radioembolization from Nordion’s three European TheraSphere Centres of Excellence. The symposium’s chairman, Stefan Pluntke, a medical oncologist from Essen Mitte hospital, Germany, will moderate the following three sessions from key presenters:

  • “Targeted liver cancer therapy in the windy city. The Chicago experience with TheraSphere”— Riad Salem, interventional oncologist, Northwestern University, Chicago, USA
  • “The future is clear. The Milan experience with TheraSphere”—Vincenzo Mazzaferro, liver transplant surgeon, Istituto Tumori, Milan, Italy
  • “The lesson from Essen. Latest insights on the use of TheraSphere”—Jörg Schlaak, gastroenterologist and hepatologist, Essen University Hospital, Essen, Germany